Opinion: India is ready — are we? Why Utah should be doubling down on India
India isn't just rising — it's ready. After two weeks on the ground meeting with innovation hubs, manufacturing leaders and government partners from Mumbai to Hyderabad, it's clear that India isn't just a market to watch — it's the market to be in. Across sectors including medtech, aerospace, e-mobility and agriculture, India is demonstrating rapid growth, a collaborative spirit and serious ambition.
With a government laser-focused on becoming a $5 trillion economy by 2029, a swelling consumer base and strong educational and research infrastructure, this is not just a timely moment but also a promising one for Utah companies to engage meaningfully with India.
What stood out most is how embedded innovation is at every level of India's economy. At Hyderabad's T-Hub, the country's largest innovation campus, I met startups working on everything from 360-degree flight simulators for the eVTOL market to cutting-edge healthcare diagnostics. At the Atal Innovation Center - Centre for Cellular and Molecular Biology (AIC-CCMB), a biotech incubator based in Hyderabad's Pharma Hub, I saw how India is cultivating life sciences companies like Startoon Labs, which developed an FDA-cleared wearable patch for muscle diagnostics — a device physical therapists in the United States could start using tomorrow.
India isn't developing abstract research and development concepts. These are real, export-ready technologies with teams behind them who are eager to collaborate. In fact, AIC-CCMB signed a memorandum of understanding with T-Hub to launch a life sciences program by June. More importantly, they expressed interest in forming a corridor between T-Hub and the Utah Innovation Fund to accelerate cross-border growth. We also met with the Indian Institute of Technology (IIT) Bombay and its innovation arms to explore collaboration opportunities with Utah universities, which is another step toward building long-term academic and commercial ties.
It's time to shelve outdated assumptions about Indian manufacturing. From touring facilities of electrical component makers for India's fast-growing electric rail market to visiting high-quality e-bike producers like EMotorad in the city of Pune, I saw production lines that rival those in Utah. E-Motorad, for instance, is in talks to become a white-label supplier for some of America's largest big-box retailers. This presents a prime opportunity for U.S. manufacturers looking to diversify their supply chains outside of China.
In conversations with India's national investment agency, Invest India, I learned they provide hands-on support — at no cost — for international companies looking to manufacture locally. That level of partnership, especially when backed by a pro-business government, is a game-changer for companies eyeing India as a production base to serve South Asia, the Gulf and even Africa.
What makes these opportunities particularly real is the level of government engagement. Maharashtra, India's most industrialized state, accounts for nearly 40% of the country's GDP. World Trade Center Utah is working to open discussions with its chief minister for a business trip this November. That level of access could unlock opportunities in finance, aerospace, clean energy and more.
I also had valuable discussions with the U.S. Commercial Service, which underscored the scale of India's medtech, aerospace and defense ecosystems. Major players like Lockheed Martin, Boeing and Safran are already there. As India ramps up its domestic capabilities through Make in India, it's encouraging strategic partnerships, not just contracts.
This trip reinforced what many are starting to recognize: India isn't 'next.' It's now.
If we want to help Utah companies stay globally competitive, we need to double down on our relationship with India — through innovation corridors, joint ventures, university and cultural partnerships, and bilateral business delegations.
India is open for business and eager for partners who are in it for the long haul.
World Trade Center Utah is returning in November. Join us.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hill
2 hours ago
- The Hill
Food and Drug Administration staff cuts may hinder US biomedical innovation
President Trump has rightly emphasized restoring America's economic and strategic independence — from reshoring pharmaceutical production to cutting regulatory red tape. But not all reforms are created equal. Recent restructuring efforts at the Food and Drug Administration may have been well-intentioned, but they risk undermining the very innovation and domestic capacity the president seeks to promote. In March, Health and Human Services Secretary Robert F. Kennedy Jr. announced a sweeping reorganization of the agency, which in part included the elimination of 3,500 full-time employees at the Food and Drug Administration — many of them senior scientific staff and experienced regulators who served as institutional pillars across drug review divisions. While we all support government efficiency and the secretary's efforts to create a gold-standard regulatory agency, the loss of this institutional memory risks hobbling the expedited pathways that small biotech firms rely on to deliver therapies for rare and life-threatening diseases. Unfortunately, the impact of these cuts is not theoretical. The Wall Street Journal has reported that some biotech firms have had to delay or cancel clinical trials due to lack of timely Food and Drug Administration guidance. One California biotech firm facing unpredictable delays has even turned to European regulators to move forward with a clinical trial — effectively offshoring American capital, investment and jobs. Others have reported receiving conflicting and confusing feedback from inexperienced FDA staff or no response at all on time-sensitive requests. But such issues don't just affect companies; they hurt patients, too. Innovation in gene therapies, cancer immunotherapies, and treatments for rare diseases depend on regulatory clarity and speed. Without senior staff to help clarify agency positions, decisions are either delayed or driven by less-experienced personnel unfamiliar with long-standing scientific standards. It's no surprise then that over 200 biotech CEOs, patient advocates and investors — many of them strong supporters of FDA modernization — have expressed their concerns in a letter to Senate Health, Education, Labor and Pensions Committee Chairman Bill Cassidy (R-La.). As a former member of Congress who sat on the Appropriations subcommittee overseeing the FDA, I have long supported targeted reforms to make the agency more nimble and responsive. But there is a fine line between streamlining operations and cutting the institutional capacity necessary to do the job. Removing experienced drug reviewers before an adequate backup plan can be put into place not only jeopardizes U.S. safety standards but also undermines our competitive edge. This matter is not merely a domestic problem; it's a global race. Since 2014, the number of biomedical drugs under development in China has grown twelvefold. Meanwhile, innovation in the U.S. has remained relatively flat. If trends continue, China could match or surpass the U.S. in biomedical innovation within the decade. We have seen this movie before — in semiconductors, in telecommunications, in clean energy. We cannot afford to let biotech go the same way. The Trump administration's tariff policy was designed to bring pharmaceutical manufacturing back to U.S. shores. But how can we expect capital to stay in the U.S. if our regulatory infrastructure cannot deliver? Delays and unpredictability at the FDA don't just slow down science — they push investors to look elsewhere. Even the user fee system — critical to funding timely drug reviews and a source of government revenue — has been impacted by the reduction in force. Staff who oversaw the reauthorization of the Prescription Drug User Fee Act have been laid off, raising questions about whether the agency will even be able to continue to collect user fees and whether these government cuts will actually end up costing taxpayers in the long run. Of course, Kennedy has long been a vocal advocate for health reform. His Make America Healthy Again agenda's focus on combatting chronic diseases and enhancing nutritional standards deserves attention. His focus for such reform is where his background and passion can lead to meaningful improvements. But when it comes to regulating complex biologics and therapeutics, we must be careful about taking actions that could inadvertently stymie scientific progress. President Trump's vision for American self-reliance will only succeed if it's built on a foundation of regulatory competence and stability. Swift actions should therefore be taken to restore the FDA's core functions, rehire critical staff and unfreeze the hiring of roles essential to America's leadership in biomedical science. The stakes — for patients, for innovation and for national security — are simply too high to ignore. John T. Doolittle is a former member of Congress who served on the Agriculture, Rural Development, FDA, and Related Agencies subcommittee of the Committee on Appropriations.
Miami Herald
2 hours ago
- Miami Herald
T-Mobile may be quietly planning a change customers will hate
T-Mobile has been losing customers left and right, with the company reporting a 5 basis point increase in customer churn year-over-year. This report came in the company's first-quarter earnings report for 2025, and it refers to the number of customers who canceled service. Rising prices on older rate plans, coupled with publishing plan prices that didn't include taxes, are some of the potential reasons why customer dissatisfaction with the uncarrier is growing. Don't miss the move: Subscribe to TheStreet's free daily newsletter Unfortunately, current and future T-Mobile customers may soon get some more bad news about the company's policies. This time, the issue is not with the cost of the monthly plans that consumers have to choose from, but is instead related to T-Mobile's payment installment programs. These programs allow consumers to finance smartphones, which most people choose to do because the upfront cost is simply too high. T-Mobile has offered installment plans on phones for over a decade, dubbing them "Equipment Installment Plans" or EIPs. But now evidence suggests the phone carrier is planning to change how these plans work, a move that could wind up being very unpopular. Image source: Bloomberg/Getty Images Since T-Mobile began offering phone financing, the company has always allowed customers to pay off their phones over a 24-month period. But a listing glitch on the company's site, coupled with information from internal sources, suggests that this will be changing very soon. According to The Mobile report, an internal T-Mobile document revealed that at least some devices would soon shift to a 36-month EIP. The website also temporarily showed a 36-month EIP plan for certain Samsung Galaxy Watches on the site's product pages. Related: T-Mobile's new partnership will ease major customer concern Both the internal document and the website changes have been removed, but they are still fueling rumors that longer payment plans are on the way. Of course, stretching out the financing time for phones and other devices would help the company to keep its customers for a longer period of time. When you finance a phone, you can't leave the carrier until the device has been paid off, unless you come up with the cash. This means T-Mobile could effectively lock in plan users for a whole extra year. While the change may be good for the company's bottom line and could offer cheaper prices for those financing their equipment, there are also some big downsides for users. If T-Mobile makes this change, the company will undermine the value proposition it offered to consumers years ago with "Phone Freedom," which allows customers more flexibility in what they do with their devices. A key part of "Phone Freedom" was a "New in Two" guarantee, which promised customers that they would be able to upgrade their devices every two years on select plans. If T-Mobile makes financing a phone a three-year commitment, users will not be able to upgrade the device or leave the carrier as quickly. Related: T-Mobile's new free phone deal is hard to beat A T-Mobile shift to a 36-month financing plan would bring the company's policies more in line with competitors, as both Verizon and AT&T lock users into financing their phones over 36 months. AT&T made the change to longer financing periods in mid-2021, and Verizon followed along eight months later. It remains to be seen whether the new T-Mobile policy will eventually go into effect, or if the internal document and website glitch were just test cases. It's also unclear whether this change will apply to all devices - some plans do offer the New in Two promise, so the company may honor that commitment. More Retail: Costco quietly plans to offer a convenient service for customersT-Mobile pulls the plug on generous offer, angering customersKellogg sounds alarm on unexpected shift in customer behavior Ultimately, making this big change might give customers another reason to be dissatisfied. Of course, they may not be able to act on that anger if they get stuck in one of the new 36-month contracts that lock them in for the next three years. Related: Veteran fund manager unveils eye-popping S&P 500 forecast The Arena Media Brands, LLC THESTREET is a registered trademark of TheStreet, Inc.
Miami Herald
3 hours ago
- Miami Herald
Forget T-Mobile. This new unlimited 5G offer is so good it has a waiting list
Many users have become very tired of major cell phone carriers and their shenanigans. For example, while T-Mobile managed to add more than 40 times the number of customers Verizon did in 2024, as well as nearly doubling AT&T's new customer number, the carrier has also been the subject of many customer complaints recently. Consumers have accused T-Mobile of price gouging, of obscuring plan costs by not including taxes in the listed price, and of quietly eliminating popular plan options, including Go5G PLUS and Go5G Next Plans. Don't miss the move: Subscribe to TheStreet's free daily newsletter The company also experienced a five basis point increase in customer churn in 2024, according to its 2025 first quarter earnings report – and rumor has it that it will be increasing its financing plans to 36-month-long plans instead of 24-month-long plans to tie customers to the "uncarrier" for longer. As customers become increasingly dissatisfied with the major carriers, the Mobile Virtual Network Operator is seeing an increase in market share. MVNOs offer mobile phone and data service, but don't own physical networks. Instead, they lease network capacity from network carriers. Now, there's a new offering among MVNO operators, and the deal it's offering is such a good one that it actually has a waiting list. Image source: Mordant/Bloomberg via Getty Images The competitive new cell phone plan is being offered by a big-name company that most people are already aware of: Klarna. Klarna is best known for its Buy Now, Pay Later platform, but it has announced that it is launching a cell phone plan that will operate on AT&T's network and that will be built on the Gigs' mobile services platform. Related: T-Mobile's new partnership will ease major customer concern The focus of the plan is its simplicity, with the company offering just one plan option instead of many. Currently, the plan is available only in the United States, but Klarna expects to expand to Germany, the UK, and other countries soon. The plan will offer: Unlimited 5G data that always stays at 5G speeds. Unlimited talk and text Nationwide coverageNo fees for activation or cancellation. Setup can reportedly be completed in minutes directly within the Klarna app with no need to visit a store, and customers can keep their current numbers if they prefer to do so. Ongoing plan administration will also happen right in the Klarna app, and the company promises that the onboarding process will be incredibly simple, with no more than a few taps needed. Users will also have the opportunity to manage their account within the Klarna app after signing up. More Retail: Costco quietly plans to offer a convenient service for customersT-Mobile pulls the plug on generous offer, angering customersKellogg sounds alarm on unexpected shift in customer behavior The total cost of the plan will be just $40 per month, which is a relative bargain as the average monthly cost of cell phone service in the U.S. is around $141 per month. "Consumers already know and love Klarna's super smooth services and now, with one tap in the Klarna app, they'll be up and running with their new phone plan – no hassle, no hidden fees, just great value," the Sebastian Siemiatkowski, CEO and co-founder of Klarna said in a statement. Klarna already has 25 million active users in the United States, and the company is hoping that its new foray into the mobile phone industry will meet a growing customer demand for a simple solution, as the company indicated their consumer research found many Americans believe mobile phone plan management is too complicated. Related: T-Mobile shares game-changing tech, free for anyone to try Co-founder and CEO of Gigs, Hermann Frank, has described Klarna's entry into the mobile market as a step towards a new connectivity between teelecoms and financial services, while also indicating that Klarna's new plan is a major upgrade for consumers compared to current phone offerings. Unfortunately, not everyone will be able to get in on this new plan when the service launches in the coming weeks. There's a waitlist already for U.S. users, so those who are interested will need to sign up within the Klarna app to get their chance at accessing the plan. Related: Veteran fund manager unveils eye-popping S&P 500 forecast The Arena Media Brands, LLC THESTREET is a registered trademark of TheStreet, Inc.
